Sökning: onr:"swepub:oai:DiVA.org:uu-498943" > Patient-reported ou...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06574naa a2200637 4500 | |
001 | oai:DiVA.org:uu-498943 | |
003 | SwePub | |
008 | 230322s2022 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4989432 URI |
024 | 7 | a https://doi.org/10.1182/blood.20220154782 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Elsawy, Mahmoudu Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada.;Dalhousie Univ, Div Hematol, Dept Med, QEII Bethune Bldg,Suite 430 Bethune Bldg, Halifax, NS B3H 2Y9, Canada.4 aut |
245 | 1 0 | a Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma |
264 | 1 | b American Society of Hematology,c 2022 |
338 | a print2 rdacarrier | |
520 | a Here, we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy vs standard-of-care (SOC) therapy in second-line relapsed/refractory large B-cell lymphoma (R/R LBCL) from the pivotal randomized phase 3 ZUMA-7 study of axicabtagene ciloleucel (axi-cel) vs SOC. PRO instruments were administered at baseline, day 50, day 100, day 150, month 9, and every 3 months from randomization until 24 months or an event-free survival event. The quality of life (QoL) analysis set comprised patients with a baseline and >= 1 follow-up PRO completion. Pre-specified hypotheses for Quality of Life Questionnaire-Core 30 (QLQ-C30) physical functioning, global health status/QoL, and EQ-5D-5L visual analog scale (VAS) were tested using mixed-effects models with repeated measures. Clinically meaningful changes were defined as 10 points for QLQ-C30 and 7 for EQ-5D-5L VAS. Among 359 patients, 296 (165 axi-cel, 131 SOC) met inclusion criteria for QoL analysis. At day 100, statistically significant and clinically meaningful differences in mean change of scores from baseline were observed favoring axi-cel over SOC for QLQ-C30 global health status/QoL (estimated difference 18.1 [95% confidence interval (CI), 12.3-23.9]), physical functioning (13.1 [95% CI, 8.0-18.2]), and EQ-5D-5L VAS (13.7 [95% CI, 8.5-18.8]; P < .0001 for all). At day 150, scores significantly favored axi-cel vs SOC for global health status/QoL (9.8 [95% CI, 2.6-17.0]; P = .0124) and EQ-5D-5L VAS (11.3 [95% CI, 5.4-17.1]; P = .0004). Axi-cel showed clinically meaningful improvements in QoL over SOC. Superior clinical outcomes and favorable patient experience with axi-cel should help inform treatment choices in second-line R/ R LBCL. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
700 | 1 | a Chavez, Julio C.u H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.4 aut |
700 | 1 | a Avivi, Iritu Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Hematol Inst, Tel Aviv, Israel.;Tel Aviv Univ, Sacker Fac Med, Tel Aviv, Israel.4 aut |
700 | 1 | a Larouche, Jean-Francoisu Ctr Hosp Univ CHU Quebec, Hop Enfant Jesus, Quebec City, PQ, Canada.4 aut |
700 | 1 | a Wannesson, Lucianou Ist Oncol Svizzera Italiana, Bellinzona, Switzerland.4 aut |
700 | 1 | a Cwynarski, Kateu Univ Coll London Hosp Natl Hlth Serv NHS Fdn Trus, Dept Haematol, London, England.4 aut |
700 | 1 | a Osman, Kerenu Icahn Sch Med Mt Sinai, New York, NY 10029 USA.4 aut |
700 | 1 | a Davison, Kellyu McGill Univ, Royal Victoria Hosp, Hlth Ctr, Montreal, PQ, Canada.4 aut |
700 | 1 | a Rudzki, Jakob D.u Med Univ Innsbruck, Univ Clin Internal Med, Dept Hematol & Oncol, Innsbruck, Austria.4 aut |
700 | 1 | a Dahiya, Saurabhu Univ Maryland, Greenebaum Comprehens Canc Ctr, Transplant & Cellular Therapy Program, Med Ctr, Baltimore, MD USA.4 aut |
700 | 1 | a Dorritie, Kathleenu Univ Pittsburgh, Med Ctr UPMC, Hillman Canc Ctr, Pittsburgh, PA USA.4 aut |
700 | 1 | a Jaglowski, Samanthau Ohio State Univ, Comprehens Canc Ctr, Blood & Marrow Transplant Program, Columbus, OH 43210 USA.4 aut |
700 | 1 | a Radford, Johnu Christie NHS Fdn Trust, Div Canc Sci, Manchester, Lancs, England.;Univ Manchester, Manchester, Lancs, England.4 aut |
700 | 1 | a Morschhauser, Francku Univ Lille, CHU Lille, Grp Rech Formes Injectables & Technol Assoc, Lille, France.4 aut |
700 | 1 | a Cunningham, Davidu Royal Marsden NHS Fdn Trust, London, England.4 aut |
700 | 1 | a Martin Garcia-Sancho, Alejandrou Salamanca Univ Hosp, Ctr Invest Biomed Red Canc CIBERONC, Inst Biomed Res Salamanca IBSAL, Hematol Dept, Salamanca, Spain.4 aut |
700 | 1 | a Tzachanis, Dimitriosu Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.4 aut |
700 | 1 | a Ulrickson, Matthew L.u Banner MD Anderson Canc Ctr, Gilbert, AZ USA.4 aut |
700 | 1 | a Karmali, Reemu Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol & Oncol, Chicago, IL 60611 USA.4 aut |
700 | 1 | a Kekre, Natashau Ottawa Hosp, Ottawa, ON, Canada.4 aut |
700 | 1 | a Thieblemont, Catherineu Univ Paris, DMU DHI, Hematooncol, Hop St Louis, Paris, France.4 aut |
700 | 1 | a Enblad, Gunillau Uppsala universitet,Cancerimmunterapi4 aut0 (Swepub:uu)gunienbl |
700 | 1 | a Dreger, Peteru Heidelberg Univ, Dept Med, Heidelberg, Germany.4 aut |
700 | 1 | a Malladi, Ramu Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England.;Univ Hosp Birmingham NHS Fdn Trust, Cambridge, England.4 aut |
700 | 1 | a Joshi, Namitau OPEN Hlth, Bethesda, MD USA.4 aut |
700 | 1 | a Wang, Wei-Jhihu OPEN Hlth, Bethesda, MD USA.4 aut |
700 | 1 | a Solem, Caitlyn T.u OPEN Hlth, Bethesda, MD USA.4 aut |
700 | 1 | a Snider, Julia Thorntonu Kite, Santa Monica, CA USA.4 aut |
700 | 1 | a Cheng, Paulu Kite, Santa Monica, CA USA.4 aut |
700 | 1 | a To, Christinau Kite, Santa Monica, CA USA.4 aut |
700 | 1 | a Kersten, Marie Joseu Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC,Stichting Hematooncol Volwassenen N, Amsterdam, Netherlands.4 aut |
710 | 2 | a Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada.;Dalhousie Univ, Div Hematol, Dept Med, QEII Bethune Bldg,Suite 430 Bethune Bldg, Halifax, NS B3H 2Y9, Canada.b H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.4 org |
773 | 0 | t Bloodd : American Society of Hematologyg 140:21, s. 2248-2260q 140:21<2248-2260x 0006-4971x 1528-0020 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-498943 |
856 | 4 8 | u https://doi.org/10.1182/blood.2022015478 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.